Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Rectal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 4Nivolumab 3sintilimab 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Bevacizumab 2vicriviroc 1trifluridine tipiracil drug combination 1spartalizumab 1relatlimab 1regorafenib 1epacadostat 1dabrafenib 1copanlisib 1binimetinib 1atezolizumab 1Tiragolumab 1Irinotecan 1Immune Checkpoint Inhibitors 1Fulvestrant 1E7046 1Cetuximab 1Capecitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Spinocerebellar Degenerations × E7046 × Gastrointestinal × Clear all
NCT04432857 2024-06-27

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Active not recruiting
63 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡